Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
Urol Oncol. 2022 Jun;40(6):271.e1-271.e7. doi: 10.1016/j.urolonc.2022.03.015. Epub 2022 Apr 28.
Biobanking tissue of high quality and fidelity is imperative for cancer genomics research. Since it is a challenging process, we sought to develop a protocol that improves the fidelity and quantity of biobanked primary prostate cancer (CaP) tissue.
We conducted a pilot study evaluating pathologic concordance of biobanked tissue and the radical prostatectomy specimen using either standard protocol (SP) vs. next-generation protocol (NGP).
There were no significant differences in clinical and pathologic characteristics (age, BMI, preoperative PSA, prostate weight, race, final prostatectomy Gleason score, or pathologic tumor and nodal stages) between the two protocol arms. Utilization of the NGP compared to the standard protocol resulted in a significantly higher rate of pathologic concordance between the biobanked and RP specimens (61.8% vs. 37.9%, P = 0.0231) as well as a nearly two-fold increase in the amount of biobanked tumor tissue (330 mm vs. 174 mm, P < 0.001). When looking at relevant clinical and pathologic characteristics, NGP was associated with pathologic concordance on both univariate [OR 2.65 (95% CI 1.13-6.21), P = 0.025] and multivariate analysis [OR 3.11 (95% CI 1.09-8.88), P = 0.034].
Our study validates the NGP as a multidisciplinary approach for improving the fidelity and amount of biobanked primary CaP tissue for future studies. Given the challenges to banking tissue from primary CaP as tumors are often difficult to visualize grossly and are frequently multifocal, optimizing the fidelity and volume of biobanked tissue is an important step forward to improve the generalizability of genomic data as we move towards precision medicine.
生物银行高质量和保真度的组织对于癌症基因组学研究至关重要。由于这是一个具有挑战性的过程,我们试图开发一种协议,以提高生物银行原发性前列腺癌 (CaP) 组织的保真度和数量。
我们进行了一项试点研究,评估了使用标准协议 (SP) 与下一代协议 (NGP) 的生物银行组织与根治性前列腺切除术标本的病理一致性。
两组方案之间在临床和病理特征(年龄、BMI、术前 PSA、前列腺重量、种族、最终前列腺癌 Gleason 评分或病理肿瘤和淋巴结分期)方面没有显著差异。与标准方案相比,使用 NGP 可显著提高生物银行和 RP 标本之间的病理一致性率(61.8%比 37.9%,P=0.0231),同时生物银行肿瘤组织量增加近两倍(330mm 比 174mm,P<0.001)。当观察相关的临床和病理特征时,NGP 与单变量分析中的病理一致性相关[OR 2.65(95%CI 1.13-6.21),P=0.025]和多变量分析[OR 3.11(95%CI 1.09-8.88),P=0.034]。
我们的研究验证了 NGP 作为一种多学科方法,可提高未来研究中生物银行原发性 CaP 组织的保真度和数量。鉴于从原发性 CaP 中储存组织的挑战,肿瘤通常难以肉眼观察,并且通常是多灶性的,因此优化生物银行组织的保真度和体积是朝着精准医学方向提高基因组数据通用性的重要一步。